Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis

Inclusion Criteria: * Male or female subjects, aged between 18 and 60 years-old; * Presence of skin lesion(s) characteristic of Tinea Pedis, with diagnosis confirmed by direct mycological exam; * Absence of previous antifungic treatment for the current lesion(s) under study; * Absence of other significant diseases which, at physician's discretion, could have an impact on subject's participation in the trial, according to protocol requirements and study evaluations: medical history, blood pressure and heart rate, physical examination and screening laboratory tests; * Ability to understand the nature and objectives of the trial, including its risks and adverse events; willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by Informed Consent Form signature. Exclusion Criteria: * Known hypersensitivity to ketoconazole or chemically related compounds; history of serious adverse reactions; * Current evidence of clinically significant diseases which, at physician's discretion, prevent subject's participation in the trial and/or expose the subject to risks other than what is normally expected; * Use of medications that, at principal investigator's discretion, might expose the subject to risks other than what is normally expected; * Screening laboratory tests results showing clinically relevant deviations that, due to potential risks, prevent participation in the trial, at the researcher's discretion; * Drugs addiction, including alcohol; * Use of any previous treatment to the lesion(s) under study that, according to principal investigator's discretion, might interfere with the study objectives; * Treatment, within 3 months before this trial, with any drugs known to have a well-established toxic potential to major organs; * Participation in any other experimental research or administration of any experimental drug within 6 months before this trial; * Positive pregnancy test, labor or miscarriage within 12 weeks before study treatment; * Any conditions, according to investigator's discretion, that prevent subjects to participate in the trial.